Merck wins use of HIV drug Isentress in paediatrics
This article was originally published in Scrip
Executive Summary
The US FDA gave its blessing on 22 December for Merck to market its HIV drug Isentress (raltegravir) for use with other antiretrovirals to treat adolescents and children as young as 2 years with the disease.